NIHR BRC-Respiratory, University of Leicester, Leicester, England, UK.
F1000Res. 2023 Oct 16;12:1344. doi: 10.12688/f1000research.141719.1. eCollection 2023.
YCharOS is a collaborative initiative aimed at characterising antibodies against the entire human proteome. As of August 2023, they have presented comprehensive knockout characterisation data for 812 antibodies and 78 proteins using techniques such as Western blot, immunoprecipitation, and immunofluorescence. YCharOS consolidates its data into reports (one protein per report) available on Zenodo, a public repository controlled by CERN, to ensure open access. To enhance the visibility of their work, the group is progressively converting their Zenodo reports into F1000 articles, collected on the YCharOS Gateway, and indexed via PubMed. Their data is also accessible through searches on the Antibody Registry. The provided data is a valuable resource for researchers when selecting antibodies for specific applications, although certain limitations should be considered. The data accumulated thus far has illuminated the extent of the problem when poorly performing antibodies are employed in research. While the scientific community was already aware that this was likely a widespread issue, the establishment of a collaborative open science project with industry partners introduces an innovative solution that holds the potential to yield significant returns on investment in the public interest. This potential is substantiated by the number of antibodies that have either been withdrawn or had their recommended usage altered by the vendor. However, despite the discovery of high-performing renewable antibodies for most of the studied proteins, this accounts for a tiny fraction of the human proteome and the commercial antibody market. To realise the full potential of this work, end-users must adjust their antibody procurement and usage practises in line with the provided data. This editorial offers a guide on how individual scientists can utilise the YCharOS data, in addition to sharing the insights gained from the data thus far with the wider scientific community.
YCharOS 是一项合作计划，旨在对针对整个人类蛋白质组的抗体进行特征描述。截至 2023 年 8 月，他们使用 Western blot、免疫沉淀和免疫荧光等技术，对 812 种抗体和 78 种蛋白质进行了全面的敲除特征描述数据。YCharOS 将其数据整合到报告中（每份报告一个蛋白质），这些报告发布在由 CERN 控制的公共存储库 Zenodo 上，以确保开放获取。为了提高工作的可见度，该团队正在逐步将其 Zenodo 报告转换为 F1000 文章，这些文章被收集在 YCharOS 网关中，并通过 PubMed 进行索引。通过在抗体注册中心进行搜索，也可以访问他们的数据。提供的数据是研究人员在为特定应用选择抗体时的宝贵资源，尽管应该考虑到某些限制。迄今为止积累的数据说明了在研究中使用性能不佳的抗体时问题的严重程度。虽然科学界已经意识到这可能是一个普遍存在的问题，但与行业合作伙伴建立一个协作的开放科学项目引入了一种创新的解决方案，有可能在公共利益方面获得投资的巨大回报。这一潜力得到了已经被供应商撤回或改变推荐使用的抗体数量的支持。然而，尽管已经发现了大多数研究蛋白质的高表现可再生抗体，但这只占人类蛋白质组和商业抗体市场的一小部分。为了充分发挥这项工作的潜力，最终用户必须根据提供的数据调整他们的抗体采购和使用实践。本社论提供了关于个体科学家如何利用 YCharOS 数据的指南，此外还与更广泛的科学界分享了迄今为止从数据中获得的见解。
